Annovis Bio wins NYSE nod on listing plan, maintains ANVS listing

Rhea-AI Filing Summary

Annovis Bio, Inc. (NYSE: ANVS) filed an 8-K on June 19, 2025 to disclose that the New York Stock Exchange has accepted the company’s previously submitted listing-compliance plan. The plan was required after Annovis fell out of compliance with NYSE continued-listing standards; acceptance removes the immediate risk of delisting and starts a defined remediation timetable. The 8-K furnishes, but does not file, a press release (Exhibit 99.1) announcing the NYSE decision. No financial statements, earnings data or major transactions were included, and the disclosure is made solely under Item 7.01 (Regulation FD) with no impact on historical financial reporting.

Investors should note that, while acceptance is a constructive step, Annovis must still meet the milestones outlined in the compliance plan to regain full compliance. The filing contains no new operational or financial metrics.

Positive

• NYSE acceptance of the listing-compliance plan eliminates the immediate delisting risk and preserves ANVS share listing on a major exchange.

Negative

• Ongoing compliance obligations: the company must still satisfy NYSE requirements within the agreed timetable, leaving residual listing risk until fully cured.
• No new financial information was provided, offering investors no additional insight into operating performance or liquidity.

Insights

Financial Analyst

TL;DR – NYSE acceptance eases immediate delisting threat but compliance work remains; limited direct financial impact.

The NYSE’s acceptance of Annovis Bio’s compliance plan is incrementally positive because it removes the near-term overhang of an involuntary delisting, which can impair liquidity and investor confidence. However, the 8-K provides no financial updates, leaving questions about the company’s path to sustained compliance. The market impact is likely modest: acceptance prevents a worst-case scenario but does not enhance revenue, cash or pipeline fundamentals. Investors should monitor future NYSE status updates to ensure the company meets the required milestones within the specified cure period.

false 0001477845 0001477845 2025-06-19 2025-06-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): June 19, 2025

ANNOVIS BIO, INC.

(Exact Name of Registrant as Specified in Charter) 

Delaware	001-39202	26-2540421
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

101 Lindenwood Drive, Suite 225
Malvern, PA 19355

(Address of Principal Executive Offices, and Zip Code)

(484) 875-3192

Registrant’s Telephone Number, Including Area Code

                       Not Applicable                       

(Former Name or Former Address, if Changed Since Last Report) 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	ANVS	New York Stock Exchange

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

Item 7.01 Regulation FD Disclosure

On June 19, 2025, the Annovis Bio, Inc. (“The Company”) issued a press release announcing acceptance of its previously submitted listing compliance plan with the New York Stock Exchange ("NYSE"). A copy of the press release is attached as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.

The information in this report (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18, of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

Exhibit Number	Description
99.1	Press Release Dated June 19, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ANNOVIS BIO, INC.
Date: June 20, 2025	By:	/s/ Maria Maccecchini
		Name: Maria Maccecchini
		Title: President and Chief Executive Officer

FAQ

Why did Annovis Bio (ANVS) file this Form 8-K on June 19, 2025?

To announce that the NYSE has accepted the company’s listing-compliance plan and to furnish a related press release.

Does NYSE acceptance mean Annovis Bio is fully compliant now?

No. Acceptance removes the immediate delisting threat, but ANVS must meet the milestones in its plan to regain full compliance.

Were any financial results or earnings figures disclosed in this filing?

No. The 8-K, filed under Item 7.01, contains no financial statements or earnings data.

What exhibit accompanied the 8-K filing?

Exhibit 99.1 is a press release dated June 19, 2025 detailing the NYSE’s acceptance of the plan.

How might this development affect Annovis Bio shareholders?

It , potentially supporting share liquidity and investor confidence, but does not alter financial fundamentals.